DK1602660T3 - Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer - Google Patents
Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorerInfo
- Publication number
- DK1602660T3 DK1602660T3 DK04712184.3T DK04712184T DK1602660T3 DK 1602660 T3 DK1602660 T3 DK 1602660T3 DK 04712184 T DK04712184 T DK 04712184T DK 1602660 T3 DK1602660 T3 DK 1602660T3
- Authority
- DK
- Denmark
- Prior art keywords
- acid derivatives
- receptor modulators
- aminophosphonic acid
- addition salts
- aminophosphonic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003039269 | 2003-02-18 | ||
| PCT/JP2004/001783 WO2004074297A1 (ja) | 2003-02-18 | 2004-02-18 | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1602660T3 true DK1602660T3 (da) | 2011-05-23 |
Family
ID=32905163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04712184.3T DK1602660T3 (da) | 2003-02-18 | 2004-02-18 | Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7456157B2 (da) |
| EP (2) | EP1602660B1 (da) |
| JP (1) | JP4564918B2 (da) |
| KR (1) | KR101005171B1 (da) |
| CN (1) | CN100344638C (da) |
| AT (1) | ATE504590T1 (da) |
| AU (1) | AU2004213297B2 (da) |
| BR (1) | BRPI0407658A (da) |
| CA (1) | CA2515574C (da) |
| CY (1) | CY1111529T1 (da) |
| DE (1) | DE602004032118D1 (da) |
| DK (1) | DK1602660T3 (da) |
| ES (1) | ES2360394T3 (da) |
| MX (1) | MXPA05008760A (da) |
| PT (1) | PT1602660E (da) |
| SI (1) | SI1602660T1 (da) |
| WO (1) | WO2004074297A1 (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482491B2 (en) * | 2002-09-19 | 2009-01-27 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
| US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| AU2005264431B2 (en) * | 2004-07-16 | 2010-08-19 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| BRPI0514316A (pt) | 2004-08-13 | 2008-06-10 | Praecis Pharm Inc | métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p) |
| US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| PT2511262T (pt) * | 2004-10-12 | 2017-03-30 | Kyorin Seiyaku Kk | Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol |
| US7888527B2 (en) | 2004-12-06 | 2011-02-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
| CA2820510A1 (en) * | 2005-09-09 | 2007-03-15 | Novartis Ag | Treatment of autoimmune diseases |
| BRPI0617077A2 (pt) * | 2005-10-07 | 2015-01-06 | Kyorin Seiyaku Kk | Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado |
| EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
| EP2099768A2 (en) * | 2006-08-04 | 2009-09-16 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
| CA2659599C (en) | 2006-08-08 | 2014-06-17 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
| NZ574011A (en) | 2006-08-08 | 2011-10-28 | Kyorin Seiyaku Kk | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| NZ576893A (en) | 2006-11-21 | 2012-01-12 | Univ Virginia Patent Found | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| EP2097371A2 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| EP3733161A1 (en) | 2007-10-12 | 2020-11-04 | Novartis AG | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| ES2572893T3 (es) | 2008-03-24 | 2016-06-02 | Kyorin Pharmaceutical Co., Ltd. | Método para la cristalización de hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol |
| EP2292594A4 (en) * | 2008-05-19 | 2014-10-15 | Kyorin Seiyaku Kk | METHOD FOR PRODUCING AN OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE |
| CN102123735A (zh) * | 2008-05-20 | 2011-07-13 | 杏林制药株式会社 | 诱导缓解维持剂 |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| AU2009276343A1 (en) * | 2008-08-01 | 2010-02-04 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| WO2010043000A1 (en) * | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators and their use thereof |
| SI2452944T1 (sl) | 2009-07-09 | 2015-01-30 | Kyorin Pharmaceutical Co., Ltd. | Difenilsulfidni derivati in zdravila, ki jih vsebujejo kot aktivno sestavino |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| AU2011249789B2 (en) | 2010-05-06 | 2015-03-19 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
| KR20130066630A (ko) | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | 자가면역 질환의 치료 |
| US8653270B2 (en) | 2010-11-22 | 2014-02-18 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| TWI519539B (zh) * | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
| US8673308B2 (en) | 2011-02-23 | 2014-03-18 | Als Therapy Development Institute | Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases |
| CN103492359B (zh) * | 2011-04-02 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途 |
| US8946301B2 (en) | 2011-11-29 | 2015-02-03 | Als Therapy Development Institute | Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis |
| EP2842937B1 (en) * | 2012-04-23 | 2018-01-17 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| EP4438037A1 (en) | 2021-01-28 | 2024-10-02 | Priothera SAS | Methods of treatment with s1p receptor modulators |
| AU2021424131A1 (en) | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
| JP2025506506A (ja) | 2022-02-16 | 2025-03-11 | プリオセラ エスエーエス | S1p受容体モジュレーターと組み合わせたcar細胞を用いた処置方法 |
| EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| WO2001098301A1 (en) | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| AU8533101A (en) | 2000-08-31 | 2002-03-13 | Merck & Co Inc | Phosphate derivatives as immunoregulatory agents |
| AU2002237988B2 (en) | 2001-01-30 | 2008-01-03 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| WO2002076995A2 (en) | 2001-03-26 | 2002-10-03 | Novartis Ag | 2-amino-propanol derivatives |
| EP1391199B1 (en) | 2001-05-10 | 2008-12-10 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| WO2003020313A1 (en) | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| JP2005112721A (ja) | 2001-11-06 | 2005-04-28 | Maruha Corp | 含窒素化合物、製造法、及びその利用方法 |
| JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
| WO2003051876A1 (en) | 2001-12-14 | 2003-06-26 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| AU2003216054B2 (en) * | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
| JP4709488B2 (ja) | 2002-01-18 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Edg受容体作動薬としてのN−(ベンジル)アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類 |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| CA2477423A1 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| PL372103A1 (en) * | 2002-05-16 | 2005-07-11 | Novartis Ag | Use of edg receptor binding agents in cancer |
| JP4166218B2 (ja) * | 2002-09-13 | 2008-10-15 | ノバルティス アクチエンゲゼルシャフト | アミノ−プロパノール誘導体 |
| MXPA05008531A (es) * | 2003-02-11 | 2005-11-17 | Irm Llc | Compuestos biciclicos novedosos y composiciones. |
| WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
-
2004
- 2004-02-18 WO PCT/JP2004/001783 patent/WO2004074297A1/ja not_active Ceased
- 2004-02-18 JP JP2005502730A patent/JP4564918B2/ja not_active Expired - Fee Related
- 2004-02-18 SI SI200431656T patent/SI1602660T1/sl unknown
- 2004-02-18 AT AT04712184T patent/ATE504590T1/de active
- 2004-02-18 EP EP04712184A patent/EP1602660B1/en not_active Expired - Lifetime
- 2004-02-18 DK DK04712184.3T patent/DK1602660T3/da active
- 2004-02-18 CA CA2515574A patent/CA2515574C/en not_active Expired - Fee Related
- 2004-02-18 PT PT04712184T patent/PT1602660E/pt unknown
- 2004-02-18 KR KR1020057015237A patent/KR101005171B1/ko not_active Expired - Fee Related
- 2004-02-18 AU AU2004213297A patent/AU2004213297B2/en not_active Ceased
- 2004-02-18 CN CNB200480004551XA patent/CN100344638C/zh not_active Expired - Fee Related
- 2004-02-18 US US10/545,790 patent/US7456157B2/en not_active Expired - Lifetime
- 2004-02-18 ES ES04712184T patent/ES2360394T3/es not_active Expired - Lifetime
- 2004-02-18 EP EP09178067A patent/EP2172472B1/en not_active Expired - Lifetime
- 2004-02-18 DE DE602004032118T patent/DE602004032118D1/de not_active Expired - Lifetime
- 2004-02-18 BR BRPI0407658-3A patent/BRPI0407658A/pt not_active Application Discontinuation
- 2004-02-18 MX MXPA05008760A patent/MXPA05008760A/es active IP Right Grant
-
2008
- 2008-06-16 US US12/213,187 patent/US7759326B2/en not_active Expired - Fee Related
-
2011
- 2011-06-06 CY CY20111100542T patent/CY1111529T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1602660T1 (sl) | 2011-06-30 |
| WO2004074297A1 (ja) | 2004-09-02 |
| DE602004032118D1 (de) | 2011-05-19 |
| US7759326B2 (en) | 2010-07-20 |
| EP2172472A2 (en) | 2010-04-07 |
| AU2004213297A1 (en) | 2004-09-02 |
| EP1602660A4 (en) | 2008-03-19 |
| CN100344638C (zh) | 2007-10-24 |
| CN1751054A (zh) | 2006-03-22 |
| US20060160771A1 (en) | 2006-07-20 |
| JP4564918B2 (ja) | 2010-10-20 |
| ATE504590T1 (de) | 2011-04-15 |
| JPWO2004074297A1 (ja) | 2006-06-01 |
| BRPI0407658A (pt) | 2006-02-21 |
| ES2360394T3 (es) | 2011-06-03 |
| EP2172472A3 (en) | 2010-06-30 |
| KR101005171B1 (ko) | 2011-01-04 |
| EP1602660A1 (en) | 2005-12-07 |
| US7456157B2 (en) | 2008-11-25 |
| CA2515574A1 (en) | 2004-09-02 |
| EP1602660B1 (en) | 2011-04-06 |
| CY1111529T1 (el) | 2015-08-05 |
| MXPA05008760A (es) | 2006-03-21 |
| AU2004213297B2 (en) | 2009-03-19 |
| CA2515574C (en) | 2012-03-13 |
| US20080275008A1 (en) | 2008-11-06 |
| KR20050109069A (ko) | 2005-11-17 |
| EP2172472B1 (en) | 2012-12-26 |
| PT1602660E (pt) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1602660T3 (da) | Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer | |
| HRP20120323T1 (en) | Diarylhydantoin compounds | |
| NO20006251L (no) | Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse | |
| TW200734314A (en) | Piperazine compounds having herbicidal action | |
| DE60210944D1 (de) | N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten | |
| DE602005023185D1 (de) | Prodrugs mit neuen biospaltbaren verbindern | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| IS7857A (is) | Setnar pýrróló-pýrasól afleiður sem kínasa hindrar | |
| WO2007067711A3 (en) | Certain chemical entities, compositions, and methods for modulating trpv1 | |
| IT1311922B1 (it) | Composti farmaceutici. | |
| DK1694318T3 (da) | (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum | |
| DK2263674T3 (da) | 10,10-Dialkyl-prostansyrederivater som midler til sænkning af intraokulært tryk | |
| DK1611144T3 (da) | Derivater af 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl-phosphonsyre og deres avendelse som n-methyl-D-aspartat (NMDA)-receptor-antagonister | |
| NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
| DK1578741T3 (da) | Aromatiske forbindelser som anti-inflammatoriske, immunmodulatoriske og anti-proliferative midler | |
| NO20054787L (no) | Indenderivater som farmasotiske midler | |
| NO20054169D0 (no) | 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. | |
| NO20052699L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
| NO20053715D0 (no) | 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| NO20063859L (no) | Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter | |
| ATE517623T1 (de) | Verwendung von methylphenidat-derivaten | |
| TW200740753A (en) | 4,5-Diarylpyrrole derivatives, preparation thereof and therapeutic use thereof | |
| ATE522214T1 (de) | Therapeutisches mittel für nahrungskompetenzstörungen im magen | |
| NO20054418L (no) | Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse |